Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC

NCT07729670 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

42

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DEVICE: Multimodal Ablation
DRUG: Neoadjuvant therapy
PROCEDURE: Surgery
DRUG: Adjunctive therapy

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences